97
Participants
Start Date
January 3, 2019
Primary Completion Date
April 29, 2020
Study Completion Date
April 29, 2020
ASN002
Daily dose of ASN002 for 32 weeks
Placebo Oral Tablet
Daily dose of Placebo Oral Tablet for 16 weeks
Maryland Laser Skin and Vein, Hunt Valley
Virginia Clinical Research, Inc., Norfolk
Sweet Hope Research Specialty, Inc, Hialeah
RM Medical Research, Inc., Miami
Pinnacle Research Group, LLC, Anniston
Dermatology Specialists Research, Louisville
Dermatologists of Greater Colombus, Bexley
Dawes Fretzin Clinical Research Group, Indianapolis
BTC Network, Fort Gratiot
Minnesota Clinical Research Center, Fridley
DelRicht Research, New Orleans
Lynn Health Science Institute, Oklahoma City
SimcoDerm Medical and Surgical Dermatology Centre, Barrie
Progressive Clinical Research, San Antonio
Advanced Clinical Research, Boise
Dermatology Research Associates, Los Angeles
Dermatology Specialists of Spokane, Spokane
ActivMed Practices and Research, Inc., Portsmouth
Wei Jing Loo Medicine Professional Corp., London
Lynderm Research Inc., Markham
G. Daniel Schachter Medicine Professional, Toronto
Innovaderm Research, Inc., Montreal
Centre de Recherche Dermatologique du Quebec metropolitain, Québec
Lead Sponsor
Asana BioSciences
INDUSTRY